XNAS · Healthcare · Biotechnology
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.11 | -1.08 | -881.82% | $5.7M | ❌ Miss | -1.26% | -20.65% | -3.16% |
| 2026-03-16 | Q4 2025 | -0.09 | 0.01 | +111.11% | $21.9M | ✅ Beat | +6.84% | -14.54% | +132.52% |
| 2025-11-12 |
| Q3 2025 |
| -0.09 |
| -0.07 |
| +22.22% |
| $2.1M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.13 | -0.09 | +30.77% | $3.0M | ✅ Beat | -3.54% | +3.29% | -3.08% |
| 2025-03-31 | Q4 2024 | -0.14 | -0.13 | +7.14% | $1.6M | ✅ Beat | -17.67% | -31.31% | -17.11% |
| 2024-11-14 | Q3 2024 | -0.19 | -0.17 | +10.53% | $3.3M | ✅ Beat | -17.00% | -31.33% | -32.00% |
| 2024-08-14 | Q2 2024 | -0.29 | -0.20 | +31.03% | $2.7M | ✅ Beat | -4.21% | +45.98% | -5.00% |
| 2024-04-08 | Q4 2023 | -0.28 | -0.28 | +0.00% | $1.8M | ➖ Inline | -6.86% | -21.81% | -6.37% |
Showing last 8 quarters.